BORTEZOMIB

作品数：118被引量：230H指数：7
导出分析报告
相关作者：李娟王清刘俊茹谷景立曾丽金更多>>
相关机构：中山大学附属第一医院南京医科大学南方医科大学南方医院中山大学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金中国博士后科学基金陕西省科技攻关计划国家高技术研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
The role of proteasomes in tumorigenesis被引量：2
《Genes & Diseases》2024年第4期155-169,共15页Xiangyi Zhou Ruqing Xu Yue Wu Li Zhou Tingxiu Xiang 
supported by the National Natural Science Foundation of China(No.82172619);the Natural Science Foundation of Chongqing,China(No.CSTC2021jscx-gksb-No023);the Medical and Industrial Integration Project(China)(No.2022CDJYGRH-002).
Protein homeostasis is the basis of normal life activities,and the proteasomefamily plays an extremely important function in this process.The proteasome 2os is a concentric circle structure with twoαrings and twoβri...
关键词：BORTEZOMIB Cancer therapy IMMUNOPROTEASOME MULTIPLEMYELOMA Proteasome 20S Proteasome inhibitor Thymoproteasom 
Enhanced Precision Therapy of Multiple Myeloma Through Engineered Biomimetic Nanoparticles with Dual Targeting
《Engineering》2024年第5期178-192,共15页Ruogu Qi Shanshan Wang Jiayi Yu Tianming Lu Zhiqiang Bi Weibo Liu Yuanyuan Guo Yong Bian Jianliang Shen Xuesong Zhang Wenhao Hu 
supported by the National Natural Science Foundation of China(52073145 and 82004081);the Jiangsu Talent Professor Program,Jiangsu Innovation Project of Graduate Student(KYCX23-2192);the National Natural Science Foundation of Nanjing University of Chinese Medicine(NZY82004081);the Special Grants of China Postdoctoral Science Foundation(2021T140792).
Multiple myeloma(MM)is the second most prevalent hematological malignancy.Current MM treatment strategies are hampered by systemic toxicity and suboptimal therapeutic efficacy.This study addressed these limitations th...
关键词：Multiple myeloma BORTEZOMIB Drug delivery Dual targeting Controlled release 
A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients被引量：1
《Oncology Research》2024年第5期955-963,共9页YAN ZHANG HEYANG ZHANG JING WANG XIN WEI YI QU FENG XU LIJUN ZHANG 
supported by the“GZ Hematologic Malignancy MARKER GHROMOS of Education Department of Liaoning Province”Grant(Grant Number:07102).
Background:Bortezomib results in peripheral neuropathy(PN)in approximately 50%of patients,during multiple myeloma(MM)treatment,a complication known as Bortezomib-induced peripheral neuropathy(BIPN).The drug response v...
关键词：Multiple Myeloma Peripheral neuropathy BORTEZOMIB Bortezomib-induced peripheral neuropathy Next-generation sequencing MTHFR Serum Hcy 
Treatment Efficacy and Safety of Bortezomib Combined with Dexamethasone and Lenalidomide Chemotherapy Regimen for Multiple Myeloma
《Journal of Clinical and Nursing Research》2024年第5期7-12,共6页Changyong Yuan Na Cui Shumei Liu 
Shandong Medical Association Clinical Research Specialization(YXH2022ZX03231)。
Objective:To analyze the effect of bortezomib combined with dexamethasone and lenalidomide in the treatment of multiple myeloma.Methods:60 cases of multiple myeloma patients admitted to our hospital from January 2022 ...
关键词：Multiple myeloma BORTEZOMIB DEXAMETHASONE LENALIDOMIDE Efficacy Safety 
Bortezomib depended on PRDM1 and TP53 to exert therapeutic effect in activated B-cell-like diffuse large B-cell lymphoma
《Genes & Diseases》2024年第2期550-553,共4页Jing Tang Yue Li Jiazhu Wu Haorui Shen Hua Yin Jinhua Liang Li Wang Jianyong Li Yi Xia Wei Xu 
supported by the National Natural Science Foundation of China(No.81720108002,81700193,82170186);Jiangsu Province's Medical Elite Programme(China)(No.ZDRCA2016022);Project of National Key Clinical Specialty(China),Jiangsu Provincial Special Program of Medical Science(China)(No.BE2017751);National Science and Technology Major F Project(China)(No.2018ZX09734007);Nature Science Foundation for Youths of Jiangsu Province,China(No.BK20220719);China Postdoctoral Science Foundation(No.2021M691336);Jiangsu Post doctoral Science Foundation(China)(No.2021K083A).
PR/SET domain 1(PRDM1)gene is located on chromosome 6q21,encoding the B lymphocyte-induced maturation protein 1(BLIMP1).1 It is reported that loss of PRDM1 function is exacerbated in activated B-cell-like(ABC)-diffuse...
关键词：PRDM1 TP53 THERAPEUTIC 
Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells
《Cancer Drug Resistance》2024年第1期869-889,共21页Leonie De Wilt Bartosz Kamil Sobocki Gerrit Jansen Hessan Tabeian Steven de Jong Godefridus J.Peters Frank Kruyt 
grant VU2006-3567 from the Dutch Cancer Society.
Aim:The therapeutic targeting of the tumor necrosis factor(TNF)-related apoptosis-inducing ligand(TRAIL)death receptors in cancer,including non-small cell lung cancer(NSCLC),is a widely studied approach for tumor sele...
关键词：TRAIL BORTEZOMIB resistance SENSITIZATION Bcl-2 family lipid rafts CYTOKINES 
Complete blood and urine paraprotein tests as response assessments in multiple myeloma patients treated with bortezomib,cyclophosphamide,and dexamethasone
《Chronic Diseases and Translational Medicine》2024年第1期62-68,共7页Xialu Lan Fujing Zhang Chen Yang Wei Su Jianhua Du Shuangjiao Liu Miao Chen Bing Han Daobin Zhou Junling Zhuang 
National High Level Hospital Clinical Research Funding(Grant/Award Number:2022-PUMCH-B-048);Capital Health Development Scientific Research Fund(Grant/Award Number:2022-2-4013).
Background: This study assessed the effect of standardized efficacy markers on prognosis in patients with newly diagnosed multiple myeloma(MM)during the induction phase of treatment with bortezomib,cyclophosphamide,an...
关键词：BORTEZOMIB light chain subtype multiple myeloma response assessment 
Efficacy of different regimens and prognostic factors in patients with first relapsed multiple myeloma treated after front-line bortezomib,cyclophosphamide,and dexamethasone
《China Medical Abstracts(Internal Medicine)》2024年第1期56-56,共1页陈苗 
Objective To.analyze the efficacy of second-line regimens and prognostic factors in patients with firstrelapsed multiple myeloma (MM) treated with bortezomib,cyclophosphamide,and dexamethasone(BCD).Methods Clinical da...
关键词：regimen PATIENTS RELAPSE 
Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation被引量：2
《Acta Biochimica et Biophysica Sinica》2023年第12期1884-1891,共8页Shuhan Jin Bo Li Bibo Zhang Xuejie Gao Xinyan Jia Li Xu Shuaikang Chang Ke Hu Guanli Wang Zhijian Xu Ting Zhang Dongliang Song Guang Yang Xiaosong Wu Huabin Zhu Cheng Huang Yumeng Lu Jumei Shi Weiliang Zhu Gege Chen 
supported by grants from the National Natural Science Foundation of China (Nos.81971529,81900212,82170200,82070224,81900210,and 81900207).
Multiple myeloma(MM)is characterized by excessive aggregation of B-cell-derived malignant plasma cells in the hematopoietic system of bone marrow.Previously,we synthesized an innovative molecule named dihydrocelastrol...
关键词：dihydrocelastrol multiple myeloma JAK2/STAT3 PSMB5 bortezomib resistance 
Bortezomib-Induced Bilateral Eye Swelling and Cutaneous Adverse Reaction in a Patient with Plasma Cell Leukemia—A Case Report
《Case Reports in Clinical Medicine》2023年第11期452-456,共5页Azeezat Ariwoola Ehab A. M. Elagab Tahira Fardous Saburi Oyewale Sara Parisi Heather Williams Amal M. Shediwah Islam A. Mahmoud Ratesh Khillan 
Bortezomib, a proteasome inhibitor, is an established therapy against plasma cell leukemia—a variant of plasma cell dyscrasias. Its most frequent side effects have been listed as peripheral neuropathy, neuropathic pa...
关键词：Plasma Cell Leukemia HEMATOLOGY BORTEZOMIB CHEMOTHERAPY 
全选清除导出
共12页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部